NewsBenzingaPasithea Therapeutics公布PAS-004抑制剂I期剂量递增试验；宣布未观察到剂量限制性毒性；无受试者停用PAS-004；未观察到3级或更高级别不良事件 Pasithea Therapeutics公布PAS-004抑制剂I期剂量递增试验；宣布未观察到剂量限制性毒性；无受试者停用PAS-004；未观察到3级或更高级别不良事件 Benzinga 2026.10.23 13:20 (GMT+0) Open on Benzinga Other news Mark Cuban Says AI Agents Can Be Like ‘Cockroaches’ That Find Ways Into Systems, But Defenders Can Fight Back With AI: ‘We’ve Always Had Hacks’ Nucor Has What It Takes To Capitalize On The Tailwinds In The Steel Market. (NYSE:NUE) Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript China Is Winning Tomorrow, But Losing Today Cathay General Bancorp Stock: Strong ROE Loan Re-Pricing In A Higher Rate (NASDAQ:CATY) Hercules Capital Stock: Close To A Buy, But Not Before 3Q26 (NYSE:HTGC)
Mark Cuban Says AI Agents Can Be Like ‘Cockroaches’ That Find Ways Into Systems, But Defenders Can Fight Back With AI: ‘We’ve Always Had Hacks’
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript
